^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Colon Cancer
    Regimen:mFOLFOX6 (5-fluorouracil + leucovorin calcium + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Colon cancer: Systemic therapy for advanced or metastatic disease…mFOLFOX6
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ann Oncol
    Title:

    Oxaliplatin-Based Adjuvant Chemotherapy Duration (3 vs. 6 Months) for High-Risk Stage II Colon Cancer: The Randomized Phase 3 ACHIEVE-2 Trial

    Published date:
    10/25/2020
    Excerpt:
    The 3-year DFS rate was 88.2% in the 3-month arm and 87.9% in the 6-month arm (hazard ratio [HR], 1.12; 95% CI, 0.67–1.87). With CAPOX, the 3-year DFS rate was 88.2% in the 3-month arm and 88.4% in the 6-month arm (HR, 1.13; 95% CI, 0.65–1.96). The discontinuation rate in the 3- and 6-month arms was 10% and 31% for mFOLFOX6 ( P = 0.0193), and 15% and 35% for CAPOX ( P < 0.0001), respectively. The incidence of grade ≥2 PSN was significantly lower in the 3-month arm than in the 6-month arm (16% and 43%, respectively, P < 0.0001).
    DOI:
    10.1016/j.annonc.2020.10.480